Previous 10 | Next 10 |
Spruce Biosciences Inc. (SPRB) is expected to report $-0.34 for Q3 2023
Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in the Jefferies London Healthcar...
Final Enrollment in CAHmelia-203 to Exceed Target Due to Substantial Patient Interest CAHmelia-203 Topline Results Anticipated in the First Quarter of 2024 CAHmelia-204 Completion of Enrollment Anticipated in Early First Quarter of 2024 Spruce Biosciences, Inc. (Nasd...
2023-09-12 14:05:37 ET More on Spruce Seeking Alpha’s Quant Rating on Spruce Biosciences Historical earnings data for Spruce Biosciences Financial information for Spruce Biosciences Spruce Biosciences: H2 2023 Data Could Be A Game Changer For CAH Treat...
Spruce Biosciences, Inc. (NASDAQ: SPRB) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 11.92% on the day to $2.55. Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing n...
2023-09-12 10:11:31 ET More on Health Care Select Sector SPDR Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR Dividend scorecard for Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) ...
2023-09-12 08:41:35 ET Summary Results from the phase 2b CAHmelia-203 clinical trial, which is using tildacerfont for the treatment of patients with classic congenital adrenal hyperplasia, expected in the 2nd half of 2023. Results from the CAHptain study, using tildacerfont for th...
2023-09-08 09:48:18 ET More on Spruce Seeking Alpha’s Quant Rating on Spruce Biosciences Historical earnings data for Spruce Biosciences Financial information for Spruce Biosciences Sizing Up Spruce Biosciences For further details see: Spru...
2023-09-08 08:27:09 ET Aziyo Biologics ( ELUT ) +19% . Verb Technology Company ( VERB ) +21% . Plus Therapeutics ( PSTV ) +15% Signs CNSid Licensing Agreement with Plus Therapeutics. Bullfrog AI ( BFRG ) +16% Announces Investor Webinar with CEO an...
Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will presen...
News, Short Squeeze, Breakout and More Instantly...
Spruce Biosciences Inc. Company Name:
SPRB Stock Symbol:
NASDAQ Market:
Spruce Biosciences Inc. Website:
Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, announced that the San Francisco Business Times and the Silicon Valley Busines...
Pairs Spruce’s Investigational Product Candidate, Tildacerfont, with HMNC’s Companion Diagnostic, the Proprietary Cortibon Genetic Selection Tool, to Treat MDD Patients Responsive to CRF 1 Receptor Antagonism Provides Spruce with Option to In-License Exclusive Worldwide ...
Significant Reduction in Dehydroepiandrosterone Sulfate ( DHEAS) Versus Placebo Observed in Women with Elevated DHEAS Levels at Baseline Increase in Serum Sex Hormone Binding Globulin (SHBG) Versus Placebo Observed Tildacerfont was Well-Tolerated with No Safety Signals ...